FLT Inhibitors
FLT (Fms-like tyrosine kinase) inhibitors target receptor tyrosine kinases, primarily FLT3 (also known as CD135), which plays a critical role in the development and proliferation of hematopoietic stem cells, particularly myeloid progenitor cells. FLT3 is a member of the Class III receptor tyrosine kinase family, sharing structural homology with PDGF receptors and KIT. Upon binding of its ligand, FLT3-ligand (FL), FLT3 dimerizes, leading to autophosphorylation of tyrosine residues in its intracellular domain. This phosphorylation event activates downstream signaling pathways, including the RAS/MAPK, PI3K/AKT, and JAK/STAT pathways, which are crucial for cell survival, proliferation, and differentiation. Aberrant FLT3 signaling, most commonly due to internal tandem duplications (ITDs) or point mutations in the tyrosine kinase domain (TKD), is a major driver in acute myeloid leukemia (AML), occurring in approximately 30% of AML cases. These mutations lead to constitutive activation of FLT3, promoting uncontrolled proliferation and inhibiting apoptosis of leukemic cells. FLT3 mutations are associated with a poorer prognosis in AML.
Beyond AML, FLT3 signaling is also implicated in other hematological malignancies and potentially in certain solid tumors, although its role is less defined. Current research and clinical progress in FLT3 inhibition are most advanced in AML. Several FLT3 inhibitors have been developed and approved, representing a significant breakthrough in targeted therapy for FLT3-mutated AML. Midostaurin was the first FLT3 inhibitor approved (in combination with chemotherapy) for newly diagnosed FLT3-mutated AML. Subsequently, more potent and selective inhibitors like gilteritinib and quizartinib have been approved for relapsed/refractory FLT3-mutated AML. Research continues to explore next-generation inhibitors with improved selectivity and efficacy, aiming to overcome resistance mechanisms. Inhibitors are broadly classified based on their selectivity and generation.
Early-generation inhibitors (e.g., midostaurin) were often multi-kinase inhibitors with activity against other tyrosine kinases. Second-generation inhibitors (e.g., gilteritinib, quizartinib) are designed to be more potent and selective for FLT3, including activity against both ITD and TKD mutations. Some inhibitors are further classified as Type I (binding to the active conformation) or Type II (binding to the inactive conformation) of the kinase. Key research tool compounds include quizartinib (AC220) in its preclinical stages. Notable challenges include the development of resistance, often through secondary mutations in the FLT3 kinase domain (e.g., the 'gatekeeper' mutation F691L) or activation of alternative signaling pathways. Toxicity, including myelosuppression and cardiovascular effects (e.g., QT prolongation), remains a concern. Combination therapy strategies are actively being investigated, pairing FLT3 inhibitors with chemotherapy, hypomethylating agents, or other targeted agents to improve response rates and overcome resistance.
The goal is to achieve deep and durable remissions in patients with FLT3-mutated AML.
